Loss-function-analysis has shown that knockdown of p62 or NRF2-transactivated genes promoted ferroptosis upon exposure of HCC cells to erastin or sorafenib, while pharmacological suppression of NRF2 aggravated the antitumor effects of sorafenib [68, 69]. Here, NFE2L2 is linked to hepatocellular carcinoma.